The Library

CD40 ligand induced cytotoxicity in carcinoma cells is enhanced by inhibition of metalloproteinase cleavage and delivery via a conditionally-replicating adenovirus

Tools

Elmetwali, Taha, Searle, Peter F., McNeish, Iain, Young, Lawrence S. and Palmer, Daniel H.. (2010) CD40 ligand induced cytotoxicity in carcinoma cells is enhanced by inhibition of metalloproteinase cleavage and delivery via a conditionally-replicating adenovirus. Molecular Cancer, Vol.9 (No.1). p. 52. ISSN 1476-4598

Preview

Text
WRAP_Young_Ligand_476-4598-9-52.pdf - Published Version
Download (1718Kb) | Preview

Official URL: http://dx.doi.org/10.1186/1476-4598-9-52

Abstract

Background
CD40 and its ligand (CD40L) play a critical role in co-ordinating immune responses. CD40 is also expressed in lymphoid malignancies and a number of carcinomas. In carcinoma cells the physiological outcome of CD40 ligation depends on the level of receptor engagement with low levels promoting cell survival and high levels inducing cell death. The most profound induction of cell death in carcinoma cells is induced by membrane-bound rather than recombinant soluble CD40L, but like other TNF family ligands, it is cleaved from the membrane by matrix metalloproteinases.

Results
We have generated a replication-deficient adenovirus expressing a mutant CD40L that is resistant to metalloproteinase cleavage such that ligand expression is retained at the cell membrane. Here we show that the mutated, cleavage-resistant form of CD40L is a more potent inducer of apoptosis than wild-type ligand in CD40-positive carcinoma cell lines. Since transgene expression via replication-deficient adenovirus vectors in vivo is low, we have also engineered a conditionally replicating E1A-CR2 deleted adenovirus to express mutant CD40L, resulting in significant amplification of ligand expression and consequent enhancement of its therapeutic effect.

Conclusions
Combined with numerous studies demonstrating its immunotherapeutic potential, these data provide a strong rationale for the exploitation of the CD40-CD40L pathway for the treatment of solid tumours.

Item Type:

Journal Article

Subjects:

R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)

Divisions:

Faculty of Medicine > Warwick Medical School

Library of Congress Subject Headings (LCSH):

Cancer -- Physiology, Cancer -- Treatment, Immune response

Journal or Publication Title:

Molecular Cancer

Publisher:

BioMed Central Ltd.

ISSN:

1476-4598

Official Date:

8 March 2010

Dates:

Date	Event
8 March 2010	Published

Volume:

Vol.9

Number:

No.1

Page Range:

p. 52

Identification Number:

10.1186/1476-4598-9-52

Status:

Peer Reviewed

Publication Status:

Published

Access rights to Published version:

Open Access

Funder:

Cancer Research UK (CRUK)

References:

1. van Kooten C, Banchereau J: CD40-CD40 ligand. J Leukoc Biol 2000,
67(1):2-17.
2. Eliopoulos AG, Young LS: The role of the CD40 pathway in the
pathogenesis and treatment of cancer. Curr Opin Pharmacol 2004,
4(4):360-7.
3. Challa A, Eliopoulos AG, Holder MJ, Burguete AS, Pound JD, Chamba A,
Grafton G, Armitage RJ, Gregory CD, Martinez-Valdez H, Young L, Gordon J:
Population depletion activates autonomous CD154-dependent survival
in biopsy like Burkitt lymphoma cells. Blood 2002, 99(9):3411-8.
4. Pham LV, Tamayo AT, Yoshimura LC, Lo P, Terry N, Reid PS, Ford RJ: A
CD40 Signalosome anchored in lipid rafts leads to constitutive
activation of NF-kappaB and autonomous cell growth in B cell
lymphomas. Immunity 2002, 16(1):37-50.
5. Baxendale AJ, Dawson CW, Stewart SE, Mudaliar V, Reynolds G, Gordon J,
Murray PG, Young LS, Eliopoulos AG: Constitutive activation of the CD40
pathway promotes cell transformation and neoplastic growth. Oncogene
2005, 24(53):7913-23.
6. Bugajska U, Georgopoulos NT, Southgate J, Johnson PW, Graber P,
Gordon J, Selby PJ, Trejdosiewicz LK: The effects of malignant
transformation on susceptibility of human urothelial cells to
CD40-mediated apoptosis. J Natl Cancer Inst 2002, 94(18):1381-95.
7. Georgopoulos NT, Steele LP, Thomson MJ, Selby PJ, Southgate J,
Trejdosiewicz LK: A novel mechanism of CD40-induced apoptosis of
carcinoma cells involving TRAF3 and JNK/AP-1 activation. Cell Death
Differ 2006, 13(10):1789-801.
8. Davies CC, Mason J, Wakelam MJ, Young LS, Eliopoulos AG: Inhibition of
phosphatidylinositol 3-kinase- and ERK MAPK-regulated protein
synthesis reveals the pro-apoptotic properties of CD40 ligation in
carcinoma cells. J Biol Chem 2004, 279(2):1010-9.
9. He TC, Zhou S, et al: A simplified system for generating recombinant
adenoviruses. Proc Natl Acad Sci USA 1998, 95(5):2509-14.
10. Malemud CJ: Matrix metalloproteinases (MMPs) in health and disease: an
overview. Front Biosci 2006, 11:1696-701.
11. Knox PG, Milner AE, et al: Inhibition of metalloproteinase cleavage
enhances the cytotoxicity of Fas ligand. J Immunol 2003, 170(2):677-85.
12. Graf D, Muller S, et al: A soluble form of TRAP (CD40 ligand) is rapidly
released after T cell activation. Eur J Immunol 1995, 25(6):1749-54.
13. Mazzei GJ, Edgerton MD, Losberger C, Lecoanet-Henchoz S, Graber P,
Durandy A, Gauchat JF, Bernard A, Allet B, Bonnefoy JY: Recombinant
soluble trimeric CD40 ligand is biologically active. J Biol Chem 1995,
270:7025-7028.
14. Heise C, Hermiston T, et al: An adenovirus E1A mutant that demonstrates
potent and selective systemic anti-tumoral efficacy. Nat Med 2000,
6(10):1134-9.
15. Afford SC, Randhawa S, et al: CD40 activation induces apoptosis in
cultured human hepatocytes via induction of cell surface fas ligand
expression and amplifies fas-mediated hepatocyte death during allograft
rejection. J Exp Med 1999, 189(2):441-6.
16. Eliopoulos AG, Dawson CW, et al: CD40-induced growth inhibition in
epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1:
involvement of TRAF3 as a common mediator. Oncogene 1996,
13(10):2243-54.
17. Eliopoulos AG, Davies C, et al: CD40 induces apoptosis in carcinoma cells
through activation of cytotoxic ligands of the tumor necrosis factor
superfamily. Mol Cell Biol 2000, 20(15):5503-15.
18. Dyson N, Guida P, et al: Adenovirus E1A makes two distinct contacts with
the retinoblastoma protein. J Virol 1992, 66(7):4606-11.
19. Fattaey AR, Harlow E, et al: Independent regions of adenovirus E1A are
required for binding to and dissociation of E2F-protein complexes. Mol
Cell Biol 1993, 13(12):7267-77.
20. Berkner KL, Sharp PA: Generation of adenovirus by transfection of
plasmids. Nucleic Acids Res 1983, 11(17):6003-20.
21. Kelly TJ Jr, Lewis AM Jr: Use of nondefective adenovirus-simian virus 40
hybrids for mapping the simian virus 40 genome. J Virol 1973,
12(3):643-52.
22. Flint SJ, Wewerka-Lutz Y, et al: Adenovirus transcription. II. RNA sequences
complementary to simian virus 40 and adenovirus 2DNA in AD2+ND1-
and AD2+ND3-infected cells. J Virol 1975, 16(3):662-73.
23. Wold WS, Deutscher SL, Takemori N, Bhat BM, Magie SC: Evidence that
AGUAUAUGA and CCAAGAUGA initiate translation in the same mRNA
region E3 of adenovirus. Virology 1986, 148(1):168-80.
24. Benedict CA, Norris PS, Prigozy TI, Bodmer JL, Mahr JA, Garnett CT,
Martinon F, Tschopp J, Gooding LR, Ware CF: Three adenovirus E3
proteins cooperate to evade apoptosis by tumor necrosis factor-related
apoptosis-inducing ligand receptor-1 and -2. J Biol Chem 2001,
276(5):3270-8.
25. Wold WS, Doronin K, Toth K, Kuppuswamy M, Lichtenstein DL, Tollefson AE:
Immune responses to adenoviruses: viral evasion mechanisms and their
implications for the clinic. Curr Opin Immunol 1999, 11(4):380-6.
26. Liu Y, Xia D, et al: Intratumoral administration of immature dendritic cells
following the adenovirus vector encoding CD40 ligand elicits significant
regression of established myeloma. Cancer Gene Ther 2005, 12(2):122-32.
27. Kikuchi T, Miyazawa N, et al: Tumor regression induced by intratumor
administration of adenovirus vector expressing CD40 ligand and naive
dendritic cells. Cancer Res 2000, 60(22):6391-5.
28. Tomihara K, Kato K, et al: Gene transfer of CD40-ligand to dendritic cells
stimulates interferon-gamma production to induce growth arrest and
apoptosis of tumor cells. Gene Ther 2008, 15(3):203-13.
29. Gonzalez-Carmona MA, Lukacs-Kornek V, Timmerman A, Shabani S,
Kornek M, Vogt A, Yildiz Y, Sievers E, Schmidt-Wolf IG, Caselmann WH,
Sauerbruch T, Schmitz V: CD40ligand-expressing dendritic cells induce
regression of hepatocellular carcinoma by activating innate and
acquired immunity in vivo. Hepatology 2008, 48(1):157-68.